Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

NCT03017352 on ClinicalTrials.gov · last registry update 2019-07-10

Finished June 2019, after enrolling 108 people. Primary outcome, as filed: Change in HbA1c. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Filip Krag Knop
Sponsor type: Other
Enrollment: 108
Started: 2016-12
Primary completion: 2019-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.